Alicia Uijl presents the results of an analysis that identified five phenotypic clusters in HFpEF with differences in medication profile, morbidity and mortality.
Guidelines need to be translated to treatment of individual patients. For support in the decision-making, a recent article was published on identifying patient profiles in HFrEF to tailor therapies.
ACC 2021 A short summary of the PARADISE-MI trial with sacubitril/valsartan compared to ramipril in MI patients is provided by prof. Pfeffer.
Prof. Januzzi talks about the biology of natriuretic peptides and discusses their performance in patients with kidney disfunction for diagnosis and prognosis of HF.
Prof. Cleland guides us through data from clinical trials that investigated pharmacological treatments in HF and discusses a treatment algorithm for HFpEF.
Many patients with HFrEF are currently not at target dose of recommended pharmacological treatments for HFrEF. A revised algorithm is needed to get patients at target doses more quickly.
Adrian Hernandez gives background information about iron metabolism and discusses results from outcome trials on iron deficiency in HF.
The 2021 update to the 2017 heart failure ECDP was just published. Prof. Januzzi explains the contribution of this document in addition to the guidelines and shares the most important updates.
In the AFFIRM-AHF trial, the effect of administration of IV ferric carboxymaltose at hospital discharge on hard outcomes was examined in patients stabilized after an acute HF episode and concomitant iron deficiency.
AHA 2020 Prof. Ponikowski presents the details of the AFFIRM-AHF trial, in which the effect of administration of IV ferric carboxymaltose shortly before discharge on clinical outcomes was examined in patients with acute HF and iron deficiency.
AHA 2020 Prof. Pfeffer gives his perspective on therapeutic options for HFrEF patients, as an increasing number of drugs have demonstrated beneficial effects in this patient population.
Prof. Van der Meer gives an introduction to the symposium about comorbidities in HF with a specific focus on hyperkalemia, that was held during the virtual ESC 2020 congress.
RAAS inhibitors can cause hyperkalemia in HF patients leading to RAASi downtitration or discontinuation. Novel potassium binders may improve management of HF patients by continuation of RAASi.
Prof. Ponikowski discusses the importance of optimization of RAASi treatment through long-term potassium control in HF patients with hyperkalemia.
Prof. Lam discusses important effects of comorbidities in HF patients and how these comorbidities may affect the use of treatments for HF.
Hyperkalemia drives suboptimal use of RAASi therapy, which is associated with increased CV risk in HF patients. Prof. Zannad presents trial results with the new potassium binders ZS-9 and patiromer.
Two cardiologists, one in an ambulatory setting and one in a hospital setting, discuss the treatment of a patient with severe heart failure following an MI over the course of two years.
Niels Grote Beverborg talks about multiple aspects of iron deficiency without anemia in HF, including outcomes, mechanisms, diagnosis, etiology and treatment options.
ESC 2020 Although there are differences between the EMPEROR-Reduced and DAPA-HF trials with regard to secondary end points, Milton Packers wants to emphasize the class effect of SGLT2 inhibitors.
Which characteristics increase clinical suspicion for amyloidosis, and how should ATTR-cardiomyopathy, a type of amyloidosis, be diagnosed and treated?
Prof. De Boer explains that the effects of SGLT2 inhibitors go beyond diuresis and that SGLT2 inhibitors are a new foundation in CV risk management, spanning from T2DM to heart failure patients.
ESC 2020 Milton Packer shares the results of the EMPEROR-Reduced trial and what these, together with those of DAPA-HF, mean for treatment of HFrEF patients.
ESC 2020 Prof. McMurray discusses briefly the outcomes of the EMPEROR-Reduced trial, evaluating the effect of empagliflozin in HFrEF patients, and compares the results to those of the DAPA-HF trial.
Two dilemmas in use of sacubitril/valsartan for heart failure patients are discussed in this presentation: Should sacubitril/valsartan be used in HFpEF patients and as initial treatment in HFrEF patients?
The co-chairs introduce the topic of this symposium by explaining that many novel therapies for HFrEF have resulted in difficulties in decision-making for management of these patients. The presentations in this series may help in decision-making in a personalized, case-based approach.
Two heart failure specialists from Glasgow, UK discuss a patient case to demonstrate that it can be difficult to diagnose HFpEF. They present tools that can help in the process of diagnosing HFpEF.
Using a case of a heart failure (HF) patient who was admitted to the hospital with acute decompensated HF (ADHF), two specialists discuss what the optimal treatment strategy in hospitalized patients should be during time of admission.
Prof. Davies talks about the interrelationship between T2DM, CVD (including heart failure) and CKD and how treatment with GLP-1RAs affects these interrelated systems.
This presentation is part of a webinar on COVID-19, ACE2 and RAAS inhibition and focusses on scientific data that is available on the ACE2 receptor and RAAS inhibitors.
As part of a webinar on COVID-19, ACE2 and RAASi, prof. Epstein presents clinical implications of discontinuation of RAASi in COVID-19 patients and strongly recommends to continue use of these medications.
As many questions arise on COVID-19, ACE2 and RAAS inhibition, 3 experts discuss some of the issues on this topic as part of a webinar.
ACC 2020 Jonathan Cunningham shares three major findings from a subanalysis of the PARAGON-HF trial in HFpEF patients.
ACC 2020 The soluble guanylate cyclase stimulator vericiguat reduced CV death and HF hospitalization compared to placebo in HFrEF patients with worsening HF.
Prof. Solomon gives a comprehensive overview of the PARAGON-HF trial and presents results of an analysis of combined data of the PARADIGM-HF and PARAGON-HF trials. With question to test your knowledge.
The EVALUATE-HF trial was set up to study the effects of sacubitril/valsartan treatment on cardiac and hemodynamic mechanisms, to look into how these may explain the observed clinical benefits.
Prof. Pieske gives a broad overview of heart failure with mid range ejection fraction, including prevalence, etiolgies and treatment options.
A subanalysis of the PIONEER-HF trial was performed to examine whether sacubitril/valsartan was effective and safe in high-risk subgroups. Prof Morrow gives a brief presentation of this analysis.
Milton Packer presents findings from the two major HF trials with sacubitril/valsartan, PARADIGM-HF and PARAGON-HF, and proposes that the definition of HFrEF should be changed to EF <50%.
AHA 2019 As a discussant of the pooled PARAGON-HF and PARADIGM-HF data, dr. Stevenson critically considers the results to get physiological clues on who should be treated and who may not benefit of ARNI therapy.
AHA 2019 A prespecified analysis of PARADIGM-HF and PARAGON-HF data allowed assessment of the effect of sacubitril/valsartan across the spectrum of ejection fractions.
AHA 2019 Prof. McMurray presents the results of an analysis of DAPA-HF comparing the effect of dapagliflozin in HF patients with and without T2DM.
CSI Paris Gianluigi Savarese tells about his study using data of the SwedeHF registry on the associations between use of betablockers and all-cause and CV mortality in HFrEF patients aged >80 years.
ESC 2019 Frank Gommans presents a study on the association between levels of corin and neprilysin, enzymes involved in the metabolism of natriuretic peptides, and clinical outcomes in HF patients.
Prof. Zannad gives an overview of CV outcome trials with SGLT2 inhibitors; first in diabetes patients and now with results in HF patients in the DAPA-HF trial.
ESC 2019 Prof. Verma gives a brief overview on SGLT2i, including data of the DAPA-HF study, potential underlying mechanisms of beneficial CV effects, and recommendations in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD.
Prof. Wanner highlights challenges in patients with CKD and HF, the effect of SGLT2 inhibitors in these patients and future perspectives.
ESC 2019 As chair of the guidelines task force, prof. Cosentino discusses the most important changes in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD, based on new evidence from CV outcomes trials.
SGLT2 inhibitors reduce CV endpoints most likely through a reduction of HF-related events. Prof. Marx discusses mechanisms potentially explaining the beneficial effects of this drug class on HF.
ESC 2019 Prof. Dirk Jan van Veldhuisen shares results of the PARAGON-HF trial, showing non-significant reductions in CV mortality and hospitalization for HF with sacubitril/valsartan vs. valsartan in HFpEF patients, and discusses subgroup analyses.
ESC 2019 A strategy of early and sustained vasodilation in acute HF patients was unable to reduce all-cause death and rehospitalization for acute HF.
ESC 2019 DAPA-HF evaluated dapagliflozin in addition to standard therapy in HFrEF patients with or without diabetes, and showed a risk reduction of 26% in worsening of HF and CV death.
ESC 2019 Sacubitril/valsartan was tested in HFpEF patients in the PARAGON-HF trial. The reduction in HF hospitalizations and CV death just missed significance, but heterogeneity was seen for the treatment effect.
ESC HF 2019 Joost Beusekamp shares results of his study on the association between potassium levels measured daily during hospitalization, treatment with RAASi and outcomes in acute HF patients.
ESC HF 2019 TmP/GFR is a novel parameter for tubular function. Lisa Emmens presents findings of her study on determinants of this parameter and its association with outcomes in HF patients.
Prof. van der Meer uses a case description to explain the issue of RAASi uptitration in the presence of hyperkalemia in HF. Furthermore, he talks about outcomes and new treatment options in HF patients with hyperkalemia.
ESC HF 2019 Jozine ter Maaten presents the results of her study on the effects of loop diuretics dosage on the ability to uptitrate RAASi in HFrEF patients and the association of loop diuretics dosage with outcomes.
During the last 30 years, clinical characteristics of HF patients have changed; nowadays, obesity is common in HF. Dr. Packer explains why obesity plays such an important role in HFpEF.
Based on a case description, prof. van der Meer explains how to diagnose HFpEF based on amyloidosis. Futhermore, he talks about current and future treatments options for patients with transthyretin amyloid cardiomyopathy.
Prof. McMurray gives an update on where we are today in the prevention of HF in diabetes patients with new diabetes drugs and talks about the next steps of treating HF in patients with and without diabetes.
Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the management of CKD with resistant hypertension.
Prof. Adriaan Voors addresses three major questions on the future of SGLT2i in HF: on routine use in T2DM and HF, use in HF without T2DM, and ongoing trials.
Prof. Lam talks about the global burden of HF and diabetes and presents registry data on practices and outcomes in patients with HF and diabetes.
What should cardiologists know about diabetes in HF patients? Martin Cowie gives an overview of how to detect and treat diabetes in HF patients.
Subodh Verma gives a presentation focusing on various proposed mechanisms through which SGLT2 inhibition can result in a reduction of CV events and HF outcomes.
ESC HF 2019 Michele Senni gives a short presentation of a subanalysis of the TRANSITION trial, comparing the rate of patients on sacubitril/valsartan after 10 weeks in de novo vs. previously diagnosed HFrEF patients.
ESC HF 2019 Prof. Rossignol talks about the AMBER trial and a prespecified analysis of HF patients. Patiromer use resulted in higher spironolactone maintenance in patients with resistant hypertension and CKD.
ACC 2019 Previous results have shown benefits in mortality and HF hospitalization with MitraClip. New data complement the previous findings and demonstrate improved quality of life with MitraClip in HF patients with secondary MR.
ACC 2019 In the MOMENTUM 3 trial, the centrifugal-flow pump HeartMate 3 was compared with the axial-flow pump HeartMate 2 in patients with advanced HF. Prof. Uriel discusses the findings and implications of this trial.
ACC 2019 Pulmonary artery pressure-guided therapy in class III HF patients met the primary efficacy and two safety endpoints at 1 year in the CardioMEMS trial.
ACC 2019 Dr. Adam DeVore discusses the results of an open-label extension study of PIONEER-HF. In this study, the effect of sacubitril/valsartan in acute HF was confirmed, showing greatest benefit when started early during hospitalisation.
Cardio Diabetes Masterclass Dubai Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.
Cardio Diabetes Masterclass Dubai Dr. Viljoen discusses findings of the Harmony Outcomes and DECLARE trials, emphasizing how different mechanisms of GLP-1RAs and SGLT2 inhibitors translate into CV benefits .
Cardio Diabetes Masterclass Dubai Prof. Montanya discusses the positive results observed with albiglutide and dapagliflozin in the Harmony Outcomes and DECLARE trial, respectively.
HFpEF: The essentials to know Prof. Burkert Pieske summarizes current treatment strategies for HFpEF and discusses new treatment options that are currently being investigated.
AHA 2018 Based on the PIONEER-HF results, Larry Allen will now confidently start guideline-recommended therapy in-hospital, for patients with acutely decompensated heart failure.
AHA 2018 Little was known about the safety of sacubitril-valsartan in acute heart failure. PIONEER-HF addressed this question and found use of the ARNI to be safe and to lower NT-proBNP.
AHA 2018 The pilot TRED-HF study evaluated a phased withdrawal of HF therapy in patients who responded well to therapy and found that this likely reflects remission rather than full recovery.
HFpEF: The essentials to know There are several diagnostic approaches for HFpEF. Dr. Borlaug discusses their usefulness and limitations.
HFpEF: The essentials to know Prof. Carolyn Lam presents six mechanisms that may underlie the pathophysiology of HFpEF. She discusses why these mechanisms may be targeted for therapy.
HFpEF: The essentials to know Prof. Adriaan Voors gives a general overview on the history, epidemiology and prognosis of HFpEF
Prof. Marx summarizes the findings of recently published CV outcome trials with SGLT2 inhibitors and discusses potential mechanisms explaining the CV effects of SGLT2 inhibitors in patients with T2DM at high CV risk.
Prof. Van der Meer describes the prevalence of hyperkalemia and its effects on the use of RAAS inhibition and discusses some potential novel potassium binders.
ESC 2018 In a randomized trial treatment with tafamidis resulted in impressive, significant reduced mortality and hospitality due to CV events in patients with ATTR-CM and HF.
Prof. Carolyn Lam recognizes six mechanisms that play a role in the pathophysiology of HFpEF. She shares evidence why these mechanisms may be targeted for therapy.
Naveed Sattar summarizes the findings of the EMPA-REG Outcome trial, and what this tells us about potential mechanisms that led to the observed CV benefit with the SGTL2 inhibitor empagliflozin.
Dr. Kotecha explains how the pathophysiologies of HFpEF and atrial fibrillation are interconnected, and what this means for management of patients with both conditions.
ACC 2018 The MOMENTUM 3 study results show a large reduction in stroke and need for reoperation, as no pump thrombosis occurred, with the new Heartmate 3 device, in comparison with the Heartmate 2.
Professor Lam lists five mechanisms in which she recognizes targets for treatment of patients with heart failure with preserved ejection fraction. These mechanisms are currently tested as therapeutic strategies.
AHA 2017 Kyla Lara presented a poster at the AHA on her research on the effect of various dietary patterns, based on Food Frequency Questionnaires, on the risk of developing heart failure.
This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona on August 28, 2017
ESC HF 2017 The HeartLogic system combines parameters including heart sound, respiratory rate and patient activity, to identify HF patients at risk of developing decompensation. Prof. Cowie discusses what remains to be done to advance the field.
ESC HF 2017 At the ESC HF congress in Paris, professor Voors shares the disappointing results of the RELAX-AHF, in which treatment with serelaxin in acute HF did not result in improvement in mortality and worsening HF
Diabetes and renal dysfunction are very common in patients with heart failure. Prof. Martin Cowie discusses the relationship and the cardiovascular effect of new therapeutic classes to control diabetes in high-risk patients.
Diabetes and diabetic kidney disease are associated with increased risk of cardiovascular disease and remarkably shortened life expectancy. Prof. Per-Henrik Groop explains the clinical implications of SGLT2-inhibtion, based on EMPA REG Outcome.
Heart failure is the most disabling and deadly complication of diabetes. Prof. John McMurray summarizes the results with various new treatments for diabetes that may affect the risk of developing heart failure.
Dr. Robert J Chilton, MD, argues that new diabetes treatments showing cardiovascular benefit require a different role of the cardiologist. The SGLT2 inhibitor empagliflozin, for example, shows both cardiovascular and renal protection, in addition to lowering glucose.
Dr. Mathew Maurer, MD, explains that TTR amyloid is an unrecognized and potentially modifiable cause of HFpEF and other age related cardiac conditions. He describes novel imaging techniques and treatments for this condition.
AHA 2016 Dirk jan van Veldhuisen shares the data of the EFFECT- HF study, in which HF patients who received ferric carboxymaltose had stable peak VO2 after 6 months of follow-up, while deterioration was seen in the control group.
Iron deficiency impairs quality of life and exercise capacity in heart failure patients. The new ESC HF guidelines recommend measuring and treating iron deficiency to help these patients.
Martin Cowie shares the very clear results of the REM-HF study addressing the question whether outcome can be improved in patients with heart failure with an implanted device, if device data are collected remotely on a weekly basis.
ESC 2016 Prof. dr. Frank Ruschitzka was chairperson in the heart failure Hot Line session at the ESC 2016. He considers the implications of the mostly neutral results observed in the presented trials on ICD, telemonitoring and stem cell therapy.
ESC 2016 Prof. Mariell Jessup (Philadelphia, PA, USA) chaired the ESC Hot Line sesion on Heart Failure. She summarises the findings of remote monitoring studies and stem cell trial and touches upon the discussion this raised.
John McMurray, MD, describes how SGLT2 inhibitors may work in preventing heart failure in diabetes.
ESC HF 2016 Kenneth Dickstein considers the increase in potassium levels that arise as a consequence of blocking the renin-angiotensin system. Hyperkalemia is often a reason for not following guideline-recommended therapy, which underlines the need for novel potassium-lowering therapy.
ESC HF 2016 The results of the EMPA-REG outcome trial have changed views on how SGLT2 inhibition may yield benefit. Naveed Sattar describes the emerging mechanistic concept based on the latest trial data.
ESC HF 2016 Conventional therapies to treat hyperkalemia are associated with clinical complications. Peter van der Meer discusses the mechanism and efficacy and safety results of two new therapeutic options that lower potassium levels: patiromer and ZS-9.
ESC HF 2016 Many HF patients are treated suboptimally, with hyperkalemia being one of the underlying reasons. Faiez Zannad considers this clinical scenario, its consequences and how it can be managed.
ESC HF 2016 David Fitchett discusses the results of the EMPA-REG OUTCOME trial: the first published trial evaluating CV endpoints with an SGLT2 inhibitor.
ESC HF 2016 Patients with both HF and diabetes have poor prognosis. Adriaan Voors reviews which currently available therapies provide benefit and which may increase risk in these patients.
Scott Solomon describes the two new pharmacologic therapies for use in patients with HFrEF that have been approved by the FDA in the past year: the heart-rate reducing agent ivabradine and sacubitril/valsartan, a combination of an ARB and a neprilysin inhibitor.
McCullough addresses the concept of a cardiorenal syndrome, specifically in the context of heart failure. in 25% of patients with acute decompensated HF, serum creatinine rises and kidney injury may develop. He considers the effects of various pharmacotherapeutic options.
ESC HF 2016 Adriaan Voors, ESC Heart Failure Guideline Task Force Co-Chairman summarises the most important changes in the 2016 guideline presented in Florence at the ESC Heart Failure Congress today, as compared with the 2012 guidelines.
Dr. Marc Pfeffer (Boston, MA, USA) considers what therapy may benefit patients across the whole spectrum of HF, and acknowledges that clearly effective therapy is still missing for HFpEF, but new options might appear at the horizon.
Dr Rajagopalan, MD, Maryland, USA reviews the utility of DPP4 inhibitors in T2DM patients with high CVD risk.
ACC 2016 Lars Køber (Copenhagen, Denmark) discusses that direct renin inhibition with aliskiren did not improve the primary outcome as compared with enalapril, in patients with heart failure, in the ATMOSPHERE trial. Interpretation of the study results was hampered by the removal of diabetic patients during the trial, based on results in other studies.
HF Summit The chairmen of the HF summit look back at a successful meeting and recapitulate what they learnt from the interaction with the audience and where most attention is needed to improve HF care.
HF Summit Different professionals involved in HF care exchange ideas about optimal multidisciplinary care of HF patients could be organised, from the perspective of a nurse, a general practitioner and a cardiologist.
HF Summit Mr. Hartshorne-Evans is a heart failure patient and he runs a patient-driven HF charity in the UK. He shares patient perspectives on the use of the word 'heart failure' and he considers how disease awareness may be improved.
HF Summit 2015 Prof. Pieske gives an overview of how to diagnose both HFrEF and HFpEF.
HF Summit 2015 - Dr. Van der Meer (Groningen, The Netherlands) summarises currently available drugs to treat HFrEF and the evidence for their efficacy.
HF Summit Dr. Kenneth Dickstein considers what are the most effective interventions in heart failure management, thereby acknowledging that certain existing management options could be applied better.
HF Summit 2015 Dr. Lam explains the differences between HFpEF and HFrEF and how this translates into (new) therapies.
AHA 2015 Prof Bertram Pitt summarises current evidence and upcoming trials of mineralocorticoid receptor antagonists in general, and of the novel non-steroidal MRA finerenone in particular.
AHA 2015 Prof. Milton Packer describes the clinical implications of the new dual inhibitor of the renin-angiotensin system and neprilysin.
ESC 2015 The PARAMETER study evaluated LCZ696, the agent that was found to be effective against heart failure in the PARADIGM-HF, in another population of patients with systolic hypertension. Prof. Bryan Williams discusses the results.
ESC 2015 The PARAMETER study evaluated LCZ696, the agent that was found to be effective against heart failure in the PARADIGM-HF, in another population of patients with systolic hypertension.
Prof John McMurray, Glasgow, explains the backgrounds of this trial with a novel ARNI and its potental implications for future Heart Failure management
Prof. Bryan Williams (London) urges the need for innovation to control systolic BP in our aging population
Lecture held by Prof Bryan Williams, MD, UCL, London, United Kingdom on 'Innovating hypertension management beyond current therapies: What are the opportunities?' held during the PACE 2014 Snapshot session in Barcelona
Dr John Teerlink highlights recent trials in the management of acute heart failure and outlines some emerging new developments
Dr. Richard Shannon, Pennsylvania, recognizes that Diabetes is a CVD equivalent and focuses on the importance that incretins can play in improving hemodynamics and outcomes in Heart Failure.
Prof Bertram Pitt, Michigan provides a brief update on Heart Failure with current evidence with MRAs ..